FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2119242783> ?p ?o ?g. }

• W2119242783 abstract "HomeCirculationVol. 113, No. 8Inflammatory Biomarkers in Acute Coronary Syndromes Free AccessReview ArticlePDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessReview ArticlePDF/EPUBInflammatory Biomarkers in Acute Coronary SyndromesPart III: Biomarkers of Oxidative Stress and Angiogenic Growth Factors Ehrin J. Armstrong, MD, MSc, David A. Morrow, MD, MPH and Marc S. Sabatine, MD, MPH Ehrin J. ArmstrongEhrin J. Armstrong From the Department of Medicine, Massachusetts General Hospital (E.J.A.), and TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital (D.A.M., M.S.S.), Boston, Mass. Search for more papers by this author , David A. MorrowDavid A. Morrow From the Department of Medicine, Massachusetts General Hospital (E.J.A.), and TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital (D.A.M., M.S.S.), Boston, Mass. Search for more papers by this author and Marc S. SabatineMarc S. Sabatine From the Department of Medicine, Massachusetts General Hospital (E.J.A.), and TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital (D.A.M., M.S.S.), Boston, Mass. Search for more papers by this author Originally published28 Feb 2006https://doi.org/10.1161/CIRCULATIONAHA.105.595546Circulation. 2006;113:e289–e292The inflammatory etiology of atherosclerosis has prompted a search for biomarkers of inflammation that predict risk for coronary artery disease and its sequelae. Within the acute coronary syndromes (ACS), inflammatory biomarkers may provide independent information regarding pathophysiology, prognosis, and optimal therapeutic strategies. Based on the hypothesis that different pathophysiological processes provide nonoverlapping information regarding risk stratification and disease management, this review series addresses biomarkers for each step in the inflammatory process leading to ACS. Parts I and II reviewed cytokines, acute-phase reactants, and biomarkers of endothelial cell activation; this part reviews biomarkers of oxidative stress and angiogenesis; part IV addresses biomarkers of extracellular matrix degradation and platelet activation.Markers of Oxidative StressOxidative stress leading to modification of low-density lipoprotein (LDL) is a central paradigm of atherogenesis and plaque destabilization. The antioxidant hypothesis of atherosclerosis has been bolstered by recent results suggesting that markers of oxidative stress may have prognostic significance in ACS (Table). Inflammatory Biomarkers in Acute Coronary SyndromesMarkerPathophysiological ContributionStrength of Clinical DataFuture Clinical Applications/DirectionsNSTEACS indicates non-ST elevation acute coronary syndromes.Oxidative stress MPOLDL oxidation, endothelial dysfunction, plaque instabilityMultiple cohortsChest pain risk stratification, NSTEACS risk stratification, possible validation as therapeutic target Ox-LDLMacrophage apoptosis, plaque progressionMultiple cohortsRequires clinical validation with outcomes PLA2LDL oxidation, arachidonic acid metabolitesMultiple cohortsRequires validation in additional studies, validation as therapeutic targetAngiogenic growth factors VEGFAngiogenesis, plaque progressionSingle cohortNSTEACS risk stratification, requires validation in cohort studies PlGFAngiogenesis, plaque progressionSingle cohortNSTEACS risk stratification, requires validation in cohort studies HGFAngiogenesis, vessel collateralizationSingle cohortPossible use in ACS without troponin elevation, requires validation in cohort studiesMyeloperoxidaseMyeloperoxidase (MPO) is a heme protein produced by neutrophils and monocytes. MPO-dependent halides, tyrosyl radicals, and reactive nitrogen species can modify LDL and thereby promote subsequent foam cell formation.1 Patients with ACS have a reduction in intracellular neutrophil MPO across both left and right coronary beds, suggesting that widespread neutrophil activation may underlie ACS.2In a prospective study, patients with ACS and elevated MPO levels had a statistically significant increase in the risk of death or myocardial infarction (MI) at 72 hours, 30 days, and 6 months.3 These differences in risk were attributable entirely to differences in mortality and MI during the first 72 hours. MPO levels were not related to levels of troponin T (TnT), C-reactive protein (CRP), or soluble CD40 ligand (sCD40L), suggesting that MPO provides independent prognostic information distinct from other established biomarkers. In a prospective study of patients presenting with chest pain, a single measurement of plasma MPO independently predicted risk of MI, even if the patient initially had undetectable TnT levels.4These 2 studies, if replicated in future trials, argue that MPO is a pathophysiologically distinct, independent predictor of risk in ACS. The most important use of MPO may be early risk stratification of patients with non-ST-elevation MI (NSTEMI).Oxidized LDLUnder conditions of high oxidant stress, lipoprotein phospholipids become progressively oxidized. These oxidant products cross link and fracture the apolipoprotein B molecule of LDL; the resulting adducts are referred to by the general term “oxidized LDL” (Ox-LDL).5 Macrophage uptake of Ox-LDL leads to foam cell formation and elaboration of proinflammatory cytokines that promote endothelial cell dysfunction, further immune cell activation, matrix metalloproteinase expression, and eventual plaque destabilization.6The 2 most extensively studied biomarkers of LDL oxidation are malondialdehyde-modified LDL (MDA-LDL) and standardized ELISA tests against a heterogeneous group of Ox-LDL.7,8 Some studies also have measured levels of minimally modified LDL, which represents an intermediate oxidation product not recognized by macrophage scavenger receptors.9 All of these studies have shown a correlation between plasma levels of oxidized LDL products and the presence and/or severity of ACS compared with normal control subjects or patients with stable coronary artery disease. Some studies have suggested that MDA-LDL may be a more specific marker in ACS than other types of Ox-LDL because platelet activation may release aldehydes that preferentially oxidize LDL to MDA-LDL.7Circulating levels of Ox-LDL were recently shown to be associated with the presence of coronary artery disease in patients undergoing elective coronary angiography10; no study has yet addressed outcomes specific to ACS. Data from the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial, however, showed that atorvastatin markedly decreased the total content of oxidized phospholipids associated with apolipoprotein B-100 in patients with ACS.11 In the future, prospective studies should be performed to ascertain whether decreased circulating levels of Ox-LDL correlate with outcomes in patients with ACS and whether circulating levels of Ox-LDL are independent of other markers such as cholesterol levels and CRP.A2 PhospholipasesA2 phospholipases (PLA2) cleave phospholipids into free fatty acids and lysophospholipids that are metabolized to generate numerous inflammatory mediators. Type II secretory PLA2 (sPLA2) promotes LDL oxidation and catalyzes phospholipid metabolism of LDL, thereby increasing the atherogenicity of LDL particles.12 Another PLA2 enzyme, lipoprotein-associated phospholipase A2 (Lp-PLA2), circulates bound to LDL.Most studies of sPLA2 and Lp-PLA2 in patients with coronary artery disease have addressed the association between circulating levels of these markers and development of coronary heart disease13 or of ischemic events in patients with stable coronary artery disease.14 In a small study of patients with ACS, an elevated sPLA2 at presentation was associated with approximately 5-fold–increased probability of coronary events over the subsequent 2 years.15 A recent analysis of patients from the Global Registry of Acute Coronary Events (GRACE) found that elevated circulating sPLA2 activity was associated with a 3-fold increased risk of death or myocardial infarction, independent of other established risk markers.15aImportantly, the risk associated with elevations in Lp-PLA2 levels is independent of CRP and, in the West of Scotland Coronary Prevention Study (WOSCOPS), was independent of statin use.13 This finding suggests that Lp-PLA2 may add novel prognostic information in ACS and that the anti-inflammatory mechanisms of statins may not affect sPLA2-mediated inflammatory pathways.Angiogenic Growth FactorsAngiogenic growth factor expression over the course of days to weeks after ACS may promote neovascularization and cardiac repair. Within atherosclerotic plaques, however, angiogenic factors promote neovascularization of the vasa vasorum and increase macrophage infiltration16; these processes may lead to intraplaque hemorrhage and atherosclerosis.Vascular Endothelial Growth FactorVascular endothelial growth factor (VEGF) is a pleiotropic growth factor that regulates endothelial cell proliferation, permeability, migration, and survival. VEGF enhances plaque growth in animal models of atherosclerosis,17 although the relevance of these findings to human trials of therapeutic VEGF administration remains controversial.In acutely ischemic myocardium, hypoxia triggers endothelial expression of VEGF mRNA transcripts within 48 hours.18 In the c7E3 Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) study, VEGF levels at presentation correlated with 72-hour risk of mortality or myocardial infarction.19 This effect remained significant at 6 months independently of other inflammatory biomarkers, including CRP, sCD40L, and MPO.3 The prognostic information provided by VEGF independently of other markers likely points toward an important role for angiogenesis in regulating myocardial repair and reperfusion after ACS.Placental Growth FactorPlacental growth factor (PlGF) is a member of the VEGF family of growth factors. PlGF is expressed in many inflammatory cell types and recently has been identified as a crucial mediator of hematopoietic stem cell recruitment and later stages of angiogenesis.20In the CAPTURE study, PlGF levels >27.0 ng/L independently predicted death or nonfatal MI at 72 hours.21 Event rates continued to diverge at 6 months, with significant differences in rates of both nonfatal MI and mortality. PlGF provided prognostic value independently of cardiac TnT, CRP, and sCD40L and identified a group of patients without elevated cardiac TnT or sCD40L who were at additional risk for an adverse event.In a large prospective study of patients presenting with chest pain but nondiagnostic ECGs, patients with ACS had increased levels of PlGF compared with patients with stable angina or noncardiac causes of chest pain.21 However, there was no difference in PlGF levels between patients with unstable angina and those with NSTEMI. In patients with no cardiac TnT elevation, patients with low levels of PlGF and sCD40L had significantly decreased 30-day risk compared with patients with elevation in one or both of these markers.These initial basic and clinical studies provide an exciting starting point for clinical applications of PlGF. More studies are necessary to delineate the expression of PlGF in atherosclerotic plaques, the time course of expression in patients with coronary artery disease, and whether PlGF levels direct therapeutic decision making in ACS.Hepatocyte Growth FactorHepatocyte growth factor (HGF) is a multipotent growth factor with significant angiogenic activity. Selective measurement of the coronary artery territory of patients 4 weeks after MI demonstrated that HGF levels were preferentially increased in the territory of the infarcted region.22 Furthermore, HGF levels correlated positively with ejection fraction and inversely with left ventricular end-diastolic volume index.Increased HGF levels predict improved outcome after ACS, possibly because patients with high HGF levels are more likely to have visible collateral circulation at coronary angiography.19 In the CAPTURE study, increased HGF levels at presentation correlated with lower risk of death or MI at 72 hours.19 Patients with normal TnT levels but low HGF levels appear to be at increased risk of death, suggesting that HGF may be a useful marker for risk stratification in patients with ACS but no troponin elevation. Notably, however, HGF levels rise rapidly after heparin administration, an effect that may confound serial measurements of HGF.This article is Part III of a 4-part article. Part I appeared in the February 14, 2006, issue of the journal (Circulation. 2006;113:e72–e75) and Part II appeared in the February 21, 2006, issue (Circulation. 2006;113:e152–e155). Part IV will appear in the March 7, 2006, issue.DisclosuresDr Morrow receives research grant support from Bayer Diagnostics, Beckman-Coulter, Biosite, Dade-Behring, and Roche Diagnostics; receives honoraria for educational presentations from Bayer, Beckman, and Dade-Behring; and serves on the advisory board of OrthoClinical Diagnostics. Dr Sabatine receives research grant support from Roche. Dr Armstrong reports no conflicts.FootnotesCorrespondence to Marc S. Sabatine, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail [email protected] References 1 Podrez E, Schmitt D, Hoff H, Hazen S. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999; 103: 1547–1560.CrossrefMedlineGoogle Scholar2 Buffon A, Biasucci L, Liuzzo G, D’Onofrio G, Crea F, Maseri A. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002; 347: 5–12.CrossrefMedlineGoogle Scholar3 Baldus S, Heeschen C, Meinertz T, Zeiher A, Eiserich J, Munzel T, Simoons M, Hamm C. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003; 108: 1440–1445.LinkGoogle Scholar4 Brennan M, Penn M, Van Lente F, Nambi V, Shishehbor M, Aviles R, Goormastic M, Pepoy M, McErlean E, Topol E, Nissen S, Hazen S. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003; 349: 1595–1604.CrossrefMedlineGoogle Scholar5 Tsimikas S, Witztum J. Measuring circulating oxidized low-density lipoprotein to evaluate coronary risk. Circulation. 2001; 103: 1930–1932.CrossrefMedlineGoogle Scholar6 Libby P. Inflammation in atherosclerosis. Nature. 2002; 420: 868–874.CrossrefMedlineGoogle Scholar7 Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation. 1998; 98: 1487–1494.CrossrefMedlineGoogle Scholar8 Holvoet P, Collen D, Van de Werf F. Malondialdehyde-modified LDL as a marker of acute coronary syndromes. JAMA. 1999; 218: 1718–1721.Google Scholar9 Ehara S, Ueda M, Naruko T, Haze K, Itoh A, Otsuka M, Komatsu R, Matsuo T, Itabe H, Takano T, Tsukamoto Y, Yoshiyama M, Takeuchi K, Yoshikawa J, Becker A. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation. 2001; 103: 1955–1960.CrossrefMedlineGoogle Scholar10 Tsmikas S, Brilakis E, Miller E, McConnell J, Lennon R, Kornman K, Witztum J, Berger P. Oxidized phospholipids, lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005; 353: 46–57.CrossrefMedlineGoogle Scholar11 Tsimikas S, Witztum J, Miller E, Sasiela W, Szarek M, Olsson A, Schwartz GG, for the Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation. 2004; 110: 1406–1412.LinkGoogle Scholar12 Niessen H, Krijnen P, Visser C, Meijer C, Hack C. Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes? Cardiovasc Res. 2003; 60: 68–77.CrossrefMedlineGoogle Scholar13 Packard C, O’Reilly D, Caslake M, McMahon A, Ford I, Cooney J, Macphee C, Suckling K, Krishna M, Wilkinson F, Rumley A, Lowe G. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000; 343: 1148–1155.CrossrefMedlineGoogle Scholar14 Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H. Circulating levels of secretory type II phospholipase A2 predict coronary events in patients with coronary artery disease. Circulation. 1999; 100: 1280–1284.CrossrefMedlineGoogle Scholar15 Kugiyama K, Ota Y, Sugiyama S, Kawano H, Doi H, Soejima H, Miyamoto S, Ogawa H, Takazoe K, Yasue H. Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris. Am J Cardiol. 2000; 86: 718–722.CrossrefMedlineGoogle Scholar15A Mallat Z, Steg PG, Benessiano J, Tanguy ML, Fox KA, Collet JP, Dabbous OH, Henry P, Carruthers KF, Dauphin A, Arguelles CS, Masliah J, Hugel B, Montalescot G, Freyssinet JM, Asselain B, Tedgui A. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. J Am Coll Cardiol. 2005; 46: 1249–1257.CrossrefMedlineGoogle Scholar16 Moulton K, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, Lo K, Gillies S, Javaherian K, Folkman J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A. 2003; 100: 4736–4741.CrossrefMedlineGoogle Scholar17 Celletti F, Waugh J, Amabile P, Brendolan A, Hilfiker P, Dake M. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med. 2001; 7: 425–429.CrossrefMedlineGoogle Scholar18 Lee S, Wolf P, Escudero R, Deutsch R, Jamieson S, Thistlethwaite P. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N Engl J Med. 2000; 342: 626–633.CrossrefMedlineGoogle Scholar19 Heeschen C, Dimmeler S, Hamm C, Boersma E, Zeiher A, Simoons M. Prognostic significance of angiogenic growth factor serum levels in patients with acute coronary syndromes. Circulation. 2003; 107: 524–530.LinkGoogle Scholar20 Autiero M, Luttun A, Tjwa M, Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003; 1: 1356–1370.CrossrefMedlineGoogle Scholar21 Heeschen C, Dimmeler S, Fichtlscherer S, Hamm C, Berger J, Simoons M, Zeiher A. Prognostic value of placental growth factor in patients with acute chest pain. JAMA. 2004; 291: 435–441.CrossrefMedlineGoogle Scholar22 Yasuda S, Goto Y, Baba T, Satoh T, Sumida H, Miyazaki S, Nonogi H. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol. 2000; 36: 115–121.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Carnevale R, Cammisotto V, Pagano F and Nocella C (2018) Effects of Smoking on Oxidative Stress and Vascular Function Smoking Prevention and Cessation, 10.5772/intechopen.78319 Seydelmann N, Liu D, Krämer J, Drechsler C, Hu K, Nordbeck P, Schneider A, Störk S, Bijnens B, Ertl G, Wanner C and Weidemann F (2016) High‐Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease, Journal of the American Heart Association, 5:6, Online publication date: 13-Jun-2016. Napoleão P, Monteiro M, Cabral L, Criado M, Ramos C, Selas M, Viegas-Crespo A, Saldanha C, Carmo M, Ferreira R and Pinheiro T (2015) Changes of soluble CD40 ligand in the progression of acute myocardial infarction associate to endothelial nitric oxide synthase polymorphisms and vascular endothelial growth factor but not to platelet CD62P expression, Translational Research, 10.1016/j.trsl.2015.07.006, 166:6, (650-659), Online publication date: 1-Dec-2015. (2015) Cocaine Karch's Pathology of Drug Abuse, Fifth Edition, 10.1201/b18962-2, (1-224), Online publication date: 30-Oct-2015. Graham S, Mwilu R and Liles W (2014) Clinical utility of biomarkers of endothelial activation and coagulation for prognosis in HIV infection, Virulence, 10.4161/viru.25221, 4:6, (564-571), Online publication date: 15-Aug-2013. Opalinska M, Stompor T, Pach D, Mikolajczak R, Fedak D, Krzanowski M, Rakowski T, Sowa-Staszczak A, Glowa B, Garnuszek P, Maurin M, Karczmarczyk U, Sulowicz W and Hubalewska-Dydejczyk A (2012) Imaging of inflamed carotid artery atherosclerotic plaques with the use of 99mTc-HYNIC-IL-2 scintigraphy in end-stage renal disease patients, European Journal of Nuclear Medicine and Molecular Imaging, 10.1007/s00259-011-2026-3, 39:4, (673-682), Online publication date: 1-Apr-2012. Smolderen K, Spertus J, Reid K, Buchanan D, Vaccarino V, Lichtman J, Bekelman D and Chan P (2012) Association of Somatic and Cognitive Depressive Symptoms and Biomarkers in Acute Myocardial Infarction: Insights from the Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status Registry, Biological Psychiatry, 10.1016/j.biopsych.2011.07.029, 71:1, (22-29), Online publication date: 1-Jan-2012. Shih J and Malhotra A (2011) Could Vitamins Be Helpful to Patients With Sleep Apnea?, Chest, 10.1378/chest.10-2017, 139:2, (237-238), Online publication date: 1-Feb-2011. Rajesh M, Mukhopadhyay P, Haskó G, Liaudet L, Mackie K and Pacher P (2010) Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells, British Journal of Pharmacology, 10.1111/j.1476-5381.2010.00712.x, 160:3, (688-700), Online publication date: 1-Jun-2010. Gómez M, Valle V, Arós F, Sanz G, Sala J, Fiol M, Bruguera J, Elosua R, Molina L, Martí H, Isabel Covas M, Rodríguez-Llorián A, Fitó M, Suárez-Pinilla M, Amezaga R and Marrugat J (2009) LDL oxidada, lipoproteína(a) y otros factores de riesgo emergentes en el infarto agudo de miocardio (estudio FORTIAM), Revista Española de Cardiología, 10.1016/S0300-8932(09)70894-2, 62:4, (373-382), Online publication date: 1-Apr-2009. Gómez M, Valle V, Arós F, Sanz G, Sala J, Fiol M, Bruguera J, Elosua R, Molina L, Martí H, Isabel Covas M, Rodríguez-Llorián A, Fitó M, Suárez-Pinilla M, Amezaga R and Marrugat J (2009) Oxidized LDL, Lipoprotein (a), and Other Emergent Risk Factors in Acute Myocardial Infarction (FORTIAM Study), Revista Española de Cardiología (English Edition), 10.1016/S1885-5857(09)71664-0, 62:4, (373-382), Online publication date: 1-Apr-2009. Ghayour-Mobarhan M, Alamdari D, Moohebati M, Sahebkar A, Nematy M, Safarian M, Azimi-Nezhad M, Reza Parizadeh S, Tavallaie S, Koliakos G and Ferns G (2009) Determination of Prooxidant—Antioxidant Balance After Acute Coronary Syndrome Using a Rapid Assay: A Pilot Study, Angiology, 10.1177/0003319709333868, 60:6, (657-662), Online publication date: 1-Dec-2009. Marković M, Ignjatović S, Majkić-Singh N and Dajak M (2009) Placental Growth Factor in Acute Coronary Syndrome Patients with Non ST-Elevation, Laboratory Medicine, 10.1309/LMK6X47RSYRCGCSB, 40:11, (675-678), Online publication date: 1-Nov-2009. Hare J, Beigi F and Tziomalos K (2008) Nitric Oxide and Cardiobiology‐Methods for Intact Hearts and Isolated Myocytes Nitric Oxide, Part G Oxidative and Nitrosative Stress in Redox Regulation of Cell Signaling, 10.1016/S0076-6879(08)01221-4, (369-392), . Martino F, Pignatelli P, Martino E, Morrone F, Carnevale R, Di Santo S, Buchetti B, Loffredo L and Violi F (2007) Early Increase of Oxidative Stress and Soluble CD40L in Children With Hypercholesterolemia, Journal of the American College of Cardiology, 10.1016/j.jacc.2007.01.082, 49:19, (1974-1981), Online publication date: 1-May-2007. Nácher M, Serrano-Mollar A and Maria Montserrat J (2007) Nuevos aspectos patogénicos en el síndrome de apneas e hipopneas durante el sueño (SAHS), Archivos de Bronconeumología, 10.1016/S0300-2896(07)71177-8, 43, (40-47), Online publication date: 1-Jan-2007. Elmas E, Lang S, Erik Dempfle C, Kälsch T, Hannak D, Sueselbeck T, Wolpert C, Borggrefe M and Brueckmann M High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction, Clinical Chemical Laboratory Medicine, 10.1515/CCLM.2007.286, 45:10 Giugliano R and Braunwald E (2006) The Year in Non–ST-Segment Elevation Acute Coronary Syndromes, Journal of the American College of Cardiology, 10.1016/j.jacc.2006.05.040, 48:2, (386-395), Online publication date: 1-Jul-2006. Zou J, Zhang X, Wang J, Wang F, Cheng J, Yang F, Song X, Wang Y, Liang Y and Shi Y (2018) The Therapeutic Efficacy of Danhong Injection Combined With Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis, Frontiers in Pharmacology, 10.3389/fphar.2018.00550, 9 Cambronero F, Marin F, Roldan V, Hernandez-Romero D, Valdes M and Lip G (2008) Biomarkers of pathophysiology in hypertrophic cardiomyopathy: implications for clinical management and prognosis, European Heart Journal, 10.1093/eurheartj/ehn538, 30:2, (139-151) February 28, 2006Vol 113, Issue 8 Advertisement Article InformationMetrics https://doi.org/10.1161/CIRCULATIONAHA.105.595546PMID: 16505179 Originally publishedFebruary 28, 2006 PDF download Advertisement SubjectsAcute Coronary Syndromes" @default.
• W2119242783 created "2016-06-24" @default.
• W2119242783 creator A5030057930 @default.
• W2119242783 creator A5058503662 @default.
• W2119242783 creator A5069400507 @default.
• W2119242783 date "2006-02-28" @default.
• W2119242783 modified "2023-10-18" @default.
• W2119242783 title "Inflammatory Biomarkers in Acute Coronary Syndromes" @default.
• W2119242783 cites W1561059299 @default.
• W2119242783 cites W1975149587 @default.
• W2119242783 cites W1994186204 @default.
• W2119242783 cites W1994215539 @default.
• W2119242783 cites W2019225851 @default.
• W2119242783 cites W2042561668 @default.
• W2119242783 cites W2066963386 @default.
• W2119242783 cites W2089331342 @default.
• W2119242783 cites W2109629533 @default.
• W2119242783 cites W2114490800 @default.
• W2119242783 cites W2121811672 @default.
• W2119242783 cites W2130541883 @default.
• W2119242783 cites W2133240166 @default.
• W2119242783 cites W2141409038 @default.
• W2119242783 cites W2146672236 @default.
• W2119242783 cites W2147282311 @default.
• W2119242783 cites W2312691634 @default.
• W2119242783 cites W2327470041 @default.
• W2119242783 doi "https://doi.org/10.1161/circulationaha.105.595546" @default.
• W2119242783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16505179" @default.
• W2119242783 hasPublicationYear "2006" @default.
• W2119242783 type Work @default.
• W2119242783 sameAs 2119242783 @default.
• W2119242783 citedByCount "34" @default.
• W2119242783 countsByYear W21192427832012 @default.
• W2119242783 countsByYear W21192427832013 @default.
• W2119242783 countsByYear W21192427832015 @default.
• W2119242783 countsByYear W21192427832016 @default.
• W2119242783 countsByYear W21192427832018 @default.
• W2119242783 countsByYear W21192427832019 @default.
• W2119242783 crossrefType "journal-article" @default.
• W2119242783 hasAuthorship W2119242783A5030057930 @default.
• W2119242783 hasAuthorship W2119242783A5058503662 @default.
• W2119242783 hasAuthorship W2119242783A5069400507 @default.
• W2119242783 hasBestOaLocation W21192427831 @default.
• W2119242783 hasConcept C126322002 @default.
• W2119242783 hasConcept C164705383 @default.
• W2119242783 hasConcept C177713679 @default.
• W2119242783 hasConcept C2777698277 @default.
• W2119242783 hasConcept C500558357 @default.
• W2119242783 hasConcept C71924100 @default.
• W2119242783 hasConceptScore W2119242783C126322002 @default.
• W2119242783 hasConceptScore W2119242783C164705383 @default.
• W2119242783 hasConceptScore W2119242783C177713679 @default.
• W2119242783 hasConceptScore W2119242783C2777698277 @default.
• W2119242783 hasConceptScore W2119242783C500558357 @default.
• W2119242783 hasConceptScore W2119242783C71924100 @default.
• W2119242783 hasIssue "8" @default.
• W2119242783 hasLocation W21192427831 @default.
• W2119242783 hasLocation W21192427832 @default.
• W2119242783 hasOpenAccess W2119242783 @default.
• W2119242783 hasPrimaryLocation W21192427831 @default.
• W2119242783 hasRelatedWork W2031269965 @default.
• W2119242783 hasRelatedWork W2119852139 @default.
• W2119242783 hasRelatedWork W2316107365 @default.
• W2119242783 hasRelatedWork W2367140913 @default.
• W2119242783 hasRelatedWork W2377483921 @default.
• W2119242783 hasRelatedWork W2384102316 @default.
• W2119242783 hasRelatedWork W2411183214 @default.
• W2119242783 hasRelatedWork W2443697580 @default.
• W2119242783 hasRelatedWork W2595649087 @default.
• W2119242783 hasRelatedWork W2737074397 @default.
• W2119242783 hasVolume "113" @default.
• W2119242783 isParatext "false" @default.
• W2119242783 isRetracted "false" @default.
• W2119242783 magId "2119242783" @default.
• W2119242783 workType "article" @default.